Aberrant CD37 expression is common in aggressive B-cell lymphoma, exemplified by 60% of patients with CD37-negative DLBCL who have inferior clinical outcome19,20, and similar findings have been recently reported for patients with follicular lymphoma62. This evidence concerns the gene CD37 and B-cell non-Hodgkin lymphoma.